Capstone invests last of funds in lipid lowering JV
This article was originally published in Scrip
Executive Summary
Capstone Therapeutics has decided to use the bulk of its remaining funds to form a joint venture with LipimetiX to develop drugs aimed at indications related to lowering blood cholesterol levels.